

**IN THE CLAIMS:**

Please cancel claims 33 and 34 without prejudice or disclaimer to the subject matter contained therein. Applicants reserve the right to pursue the subject matter of canceled claims in subsequent divisional applications.

In accordance with 37 C.F.R. § 1.121, please substitute for claim 26 the following rewritten version of the same claim, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made".

---

E 1 26. (Amended) A method for altering signal transduction in an APB domain-containing signal transduction pathway comprising administering to a patient a therapeutically effective amount of an agent which decreases binding between an APB recognition region present in a first protein and an APB domain present in a second protein, wherein said APB domain shares at least 80% sequence similarity or at least 75% sequence identity with the APB domain present in Shc.

---

**REMARKS**

**Status of the Claims**

By this amendment, claim 26 is amended and claims 33 and 34 are canceled. The cancellation of claims does not constitute acquiescence in the propriety of any rejection set forth by the Examiner. Upon entry of this Amendment, claims 26-32 and 35 will remain pending in the application.

**Claim Rejections -35 U.S.C. § 112, Second Paragraph**

Claims 26-35 are rejected by the examiner under 35 U.S.C. § 112, second paragraph, as being indefinite. Applicants respectfully request reconsideration and withdrawal of the rejection.

The examiner asserts that the term "therapeutically effective amount" in claims 26-35 is a relative term which renders the claim indefinite. Applicants respectfully disagree and direct the examiner's attention to page 8, lines 18-21 of the specification where the term